Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2371
Title: Efficacy and safety of four doses of lumiracoxib versus diclofenac in patients with knee or hip primary osteoarthritis: A phase II, four-week, multicenter, randomized, double-blind, placebo-controlled trial
Authors: Schnitzer, TJ
Beier, J.
GEUSENS, Piet 
Hasler, P
Patel, SK
Senftleber, I
Gitton, X
Moore, A.
Sloan, VS
Poor, G
Issue Date: 2004
Publisher: WILEY-LISS
Source: ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 51(4). p. 549-557
Abstract: Objective. To compare the efficacy and tolerability of the novel cyclooxygenase 2-selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). Methods. Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 mg twice daily or 400 mg once daily; placebo; or diclofenac 75 mg twice daily. Efficacy assessments included overall joint pain intensity and Western Ontario and McMaster Universities Osteoarthritis Index subscales; tolerability was evaluated by adverse event and physician reporting. Results. All lumiracoxib doses were superior to placebo in relieving pain, improving stiffness, and improving physical function after 4 weeks. At study endpoint, pain relief was comparable among all lumiracoxib dosages and similar to diclofenac. Lumiracoxib tolerability was superior to diclofenac and comparable to placebo. Conclusion. Lumiracoxib provides predictable and sustained relief from pain, stiffness, and impaired physical function in OA. Lumiracoxib shows clinically comparable efficacy and superior tolerability to diclofenac.
Notes: Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. Univ Limburg, Diepenbeek, Belgium. Felix Platter Hosp, Basel, Switzerland. Adan House Surg, Durham, England. Novartis Pharma AG, Basel, Switzerland. Novartis Pharmaceut Corp, E Hanover, NJ USA. Natl Inst Rheumatism & Physiotherapy, Budapest, Hungary.Schnitzer, TJ, Northwestern Ctr Clin Res, 710 N Lake Shore Dr,Room 1020, Chicago, IL 60611 USA.tjs@northwestern.edu
Keywords: lumiracoxib; diclofenac; pain relief; osteoarthritis
Document URI: http://hdl.handle.net/1942/2371
ISSN: 0004-3591
DOI: 10.1002/art.20525
ISI #: 000223183100007
Category: A1
Type: Journal Contribution
Validations: ecoom 2005
Appears in Collections:Research publications

Show full item record

SCOPUSTM   
Citations

51
checked on Sep 2, 2020

WEB OF SCIENCETM
Citations

42
checked on May 29, 2022

Page view(s)

44
checked on May 28, 2022

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.